Kenneth E. Thorpe, PhD

Undermining access to biologics is not the answer.

In theory, patients should benefit from drug price discounts negotiated between drug companies and insurers. In reality, they don’t, and a potential solution is stalled in Congress.

For some seniors living with chronic diseases, one particular reform may actually lead to higher out-of-pocket costs

The Biden administration recently warned that Medicare could spend $3.5 billion on a new category of Alzheimer's drugs in 2025 alone – a figure vastly higher than what experts in the field predict – leading many to question the math.

New anti-obesity drugs are a new tool in fight against overweight, but more accessibility is needed.